Our advanced medical technology & services

Our majority owned subsidiary, CellVec Pte. Ltd. focuses on the development of novel platform viral vector technologies that strive to advance genetic modification of cellular therapy through basic vector system biology design to developing novel process and manufacturing strategies. Fronted by a team of leading scientists recruited from leading academic institutions from U.K. and Singapore, CellVec is developing the first cell and gene therapy cGMP manufacturing for the region.

With the most recent FDA-approved gene therapy product – Chimeric Antigen Receptor (CAR) T-cells, for blood cancer treatments, there is an explosion in the development of cellular therapies worldwide. One of the key limiting factors globally is the acute lack of facilities with the experience to produce bespoke viral based vector cellular therapies. We believe that CellVec is strategically placed to fill the gap in this market.